Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, UT 84112, USA.
Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, UT 84112, USA; Department of Bioengineering, University of Utah, Salt Lake City, UT 84112, USA.
J Control Release. 2018 Jan 10;269:1-9. doi: 10.1016/j.jconrel.2017.10.018. Epub 2017 Oct 20.
Silver nanoparticles (AgNPs) are widely available as consumer goods, and over-the-counter or nutraceutical products used for alleged therapeutic and antibacterial properties. Among these products, AgNP topical therapy is proposed for treating patients with upper airway bacterial rhinosinusitis. While silver ion release from AgNPs in biological systems is well known, limited investigations actually characterize this silver ion release and their subsequent biological effects distinct from delivered particulate metallic silver. This is in part due to the analytical complexity and difficulty involved in distinguishing silver ion release from metallic AgNPs in biological media. Therefore, this study compared intranasal administration of AgNPs versus soluble silver ion (AgNO) control to examine their transport and biological differences in tissues. First, we compared bactericidal activities of AgNPs and AgNO in those bacteria commonly associated with clinical rhinosinusitis in vitro. Next, we evaluated silver residence time in the sinus cavity after intranasal delivery of AgNPs and AgNO to mice, and characterized tissue distribution of silver in the sinonasal mucosal epithelium. We found that AgNPs show reduced bactericidal activity compared to AgNO (i.e., MBC of 15ppm compared to 5ppm), and significantly lower residence times in the sinus cavity (AgNP concentrations of 3.76ppm after 3h compared to 9ppm for AgNO). AgNPs were not readily taken up into or through respiratory epithelium, with very low silver levels found in blood and no detectable silver measured in the olfactory bulb and brain. Results indicate that limited tissue distribution of silver detected from AgNPs is due to AgNP dissolution to silver ion. AgNPs therefore demonstrate adequate safety through limited penetration and absorption, but limited potential therapeutic efficacy as antimicrobials in nasal applications, as concentrations of silver in the sinus cavity drop below the minimum bactericidal concentration within 3h.
银纳米粒子(AgNPs)作为消费品广泛存在,非处方或营养保健品用于声称具有治疗和抗菌特性。在这些产品中,AgNP 局部治疗被提议用于治疗上呼吸道细菌性鼻-鼻窦炎患者。虽然 AgNPs 在生物系统中释放银离子是众所周知的,但实际上很少有研究对这种银离子释放及其与输送的颗粒态金属银的后续生物学效应进行特征描述。这在一定程度上是由于在生物介质中区分 AgNP 释放的银离子和金属 AgNPs 的分析复杂性和困难。因此,本研究比较了 AgNPs 与可溶性银离子(AgNO)对照物的鼻腔内给药,以检查它们在组织中的转运和生物学差异。首先,我们比较了 AgNPs 和 AgNO 在与临床鼻-鼻窦炎相关的常见细菌中的杀菌活性。接下来,我们评估了 AgNPs 和 AgNO 鼻腔给药后银在鼻窦腔内的驻留时间,并对鼻-鼻窦黏膜上皮中的银组织分布进行了特征描述。我们发现,与 AgNO 相比,AgNPs 的杀菌活性降低(即,MBC 为 15ppm 比 5ppm),并且在鼻窦腔内的驻留时间显著缩短(AgNP 浓度为 3.76ppm ,3h 后与 AgNO 的 9ppm 相比)。AgNPs 不易被呼吸道上皮吸收或穿透,血液中的银含量非常低,嗅球和大脑中未检测到银。结果表明,AgNPs 检测到的有限组织分布的银是由于 AgNP 溶解为银离子。AgNPs 因此通过有限的穿透和吸收显示出足够的安全性,但作为鼻腔应用中的抗菌剂的治疗效果有限,因为鼻窦腔内的银浓度在 3h 内降至最低杀菌浓度以下。